Document Detail

Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation: A Randomized, Placebo-Controlled Clinical Trial.
MedLine Citation:
PMID:  23380864     Owner:  NLM     Status:  Publisher    
BACKGROUND: New-onset diabetes after transplantation (NODAT) is a serious complication after kidney transplantation affecting graft and patient survival. Currently, no guidelines exist for the management of renal transplant patients with impaired glucose tolerance (IGT), a risk factor for the development of NODAT and an independent predictor of death. METHODS: In a population of 48 stable renal transplant recipients at least 6 months from time of transplantation with newly diagnosed IGT, we tested the dipeptidylpeptidase-4 inhibitor vildagliptin, the thiazolidinedione pioglitazone, or placebo for 3 months in addition to lifestyle counseling. Outcome measures were difference in change in oral glucose tolerance test between the groups and between baseline and end of study as well as change in HbA1c, serum lipids, and renal and hepatic function. RESULTS: In both treatment groups, 2-hr plasma glucose at 3 months was significantly reduced compared with baseline (vildagliptin: -20±24 mg/dL; P=0.002 and pioglitazone: -23±29 mg/dL; P=0.004), and pioglitazone also significantly improved fasting plasma glucose (-11±14 mg/dL; P=0.003), although the primary outcome (difference in change in 2-hr plasma glucose among the three groups) did not reach statistical significance. Furthermore, HbA1c was decreased in both treatment arms (vildagliptin: -0.1%±0.3%; P=0.046 and pioglitazone: -0.2%±0.3%; P=0.029). In the placebo group, no significant changes in these parameters were observed. Only mild adverse events occurred and at a similar rate in all three groups. CONCLUSIONS: These data demonstrate that both vildagliptin and pioglitazone are of potential benefit in patients with IGT after renal transplantation in addition to lifestyle modification.
Johannes Werzowa; Manfred Hecking; Michael Haidinger; Felix Lechner; Dominik Döller; Giovanni Pacini; Gunar Stemer; Johannes Pleiner; Sophie Frantal; Marcus D Säemann
Related Documents :
7857344 - Pharmacokinetics of pidotimod in elderly volunteers and in renal failure patients.
15888034 - Mdrd equations for estimation of gfr in renal transplant recipients.
7713094 - The acute effect of ioversol on kidney function: role of endothelin.
2150974 - Effect of advanced age on p-aminohippurate-induced inhibition of renal tubular secretio...
10609964 - Quantitative analysis of cardiac 3-l-nitrotyrosine during acute allograft rejection in ...
9477194 - Nephron sparing surgery for de novo renal cell carcinoma in an allograft kidney: a case...
Publication Detail:
Journal Detail:
Title:  Transplantation     Volume:  95     ISSN:  1534-6080     ISO Abbreviation:  Transplantation     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  -    
Other Details:
Languages:  ENG     Pagination:  456-462     Citation Subset:  -    
1 Clinical Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. 2 Metabolic Unit, Institute of Biomedical Engineering, National Research Council, Padova, Italy. 3 Pharmacy Department, Vienna General Hospital, Austria. 4 Coordinating Center for Clinical Studies, Medical University of Vienna, Vienna, Austria. 5 Institute for Medical Statistics, Medical University of Vienna, Vienna, Austria. 6 Address correspondence to: Marcus D. Säemann, M.D., Clinical Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  sCD200 Present in Mice Receiving Cardiac and Skin Allografts Causes Immunosuppression In Vitro and I...
Next Document:  Outcomes after liver transplantation in patients achieving a model for end-stage liver disease score...